<DOC>
	<DOCNO>NCT00491738</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , blind , placebo-controlled study design evaluate safety efficacy combine bevacizumab sunitinib relative placebo sunitinib patient metastatic RCC receive prior systemic therapy metastatic disease . The study enroll approximately 100 patient approximately 20 center United States .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Sunitinib With Without Bevacizumab First-Line Patients With Metastatic Renal Cell Cancer ( SABRE-R )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Signed Informed Consent Form Histologically confirm metastatic RCC Measurable disease , define RECIST Age ≥ 18 year ECOG performance status 0 1 Prior nephrectomy Ability capacity comply study followup procedure RCC predominantly sarcomatoid feature Prior systemic adjuvant therapy RCC Radiotherapy RCC within 28 day prior Day 1 Prior treatment bevacizumab , sunitinib , sorafenib , axitinib , thalidomide , similar agent Current need dialysis Life expectancy &lt; 12 week Current , recent , planned participation experimental drug study Inadequate organ function Active infection fever &gt; 38.5°C within 3 day start treatment History malignancy within 5 year prior Day 1 Any medical condition ( include mental illness substance abuse ) deem clinician likely interfere patient 's ability provide inform consent , cooperate , participate study , interfere interpretation result Inadequately controlled hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great CHF History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Known CNS disease except treated brain metastasis Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 1 History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure anticipation need major surgical procedure course study Serious , nonhealing wound ; active ulcer ; untreated bone fracture Known hypersensitivity component bevacizumab Pregnancy ( positive pregnancy test ) lactation Current , ongoing treatment fulldose warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>RCC</keyword>
	<keyword>Renal cell cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>Sutent</keyword>
</DOC>